Vir Biotech-GSK's COVID-19 Treatment Wins Provisional Approval In Australia

Loading...
Loading...
  • The Australian Therapeutic Goods Administration has granted provisional marketing authorization for Vir Biotechnology Inc's VIR for sotrovimab, a monoclonal antibody for COVID-19.
  • The approval covers adults and adolescents who do not require initiation of oxygen due to COVID-19 and are at increased risk of progression to hospitalization or death.
  • Vir Biotechnology developed sotrovimab in partnership with GlaxoSmithKline plc GSK
  • It is authorized for emergency use in the U.S. and has received a positive scientific opinion from CHMP in the European Union.
  • Price Action: VIR stock is up 1.14%% at $47.00, while GSK stock is down 0.55% at $41.62 during the market session on the last check Monday.
Posted In: BiotechNewsHealth CareFDAGeneralBriefsCoronavirusCovid-19
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...